See more : Investment AB Latour (publ) (LATO-B.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Third Harmonic Bio, Inc. (THRD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Third Harmonic Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Avenue Therapeutics, Inc. (ATXI) Income Statement Analysis – Financial Results
- Shanghai Voicecomm Info Tech (2495.HK) Income Statement Analysis – Financial Results
- Solid Försäkringsaktiebolag (publ) (SFAB.ST) Income Statement Analysis – Financial Results
- Kuo Toong International Co., Ltd. (8936.TWO) Income Statement Analysis – Financial Results
- Stonehorse Energy Limited (SHE.AX) Income Statement Analysis – Financial Results
Third Harmonic Bio, Inc. (THRD)
About Third Harmonic Bio, Inc.
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 35.00K | 38.00K | 0.00 | 0.00 |
| Gross Profit | -35.00K | -38.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 23.96M | 24.41M | 15.75M | 9.95M |
| General & Administrative | 19.99M | 13.30M | 3.26M | 1.17M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.99M | 13.30M | 3.26M | 1.17M |
| Other Expenses | 0.00 | 2.55M | -10.61M | -1.69M |
| Operating Expenses | 43.92M | 37.71M | 19.00M | 11.12M |
| Cost & Expenses | 43.95M | 37.71M | 19.00M | 11.12M |
| Interest Income | 13.13M | 2.55K | 5.00 | 0.00 |
| Interest Expense | 0.00 | 2.55M | 0.00 | 0.00 |
| Depreciation & Amortization | 35.00K | 38.00K | 19.00M | 11.12M |
| EBITDA | -30.79M | -35.12M | -10.61M | -1.69M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -43.95M | -37.71M | -19.00M | -11.12M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 13.13M | 2.55M | -10.61M | -1.69M |
| Income Before Tax | -30.82M | -35.16M | -29.61M | -12.81M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 2.55M | -19.00K | -1.00K |
| Net Income | -30.82M | -37.71M | -29.61M | -12.81M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.78 | -0.96 | -0.77 | -0.33 |
| EPS Diluted | -0.78 | -0.96 | -0.77 | -0.33 |
| Weighted Avg Shares Out | 39.65M | 39.38M | 38.69M | 38.69M |
| Weighted Avg Shares Out (Dil) | 39.65M | 39.38M | 38.69M | 38.69M |
Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results
U.S. IND filed for THB335 with anticipated clinical trial start during 2Q'24 Strong financial position with cash and cash equivalents totaling $269.1 million as of December 31, 2023 SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc....
Third Harmonic Bio to Participate in the 44th Annual TD Cowen Health Care Conference
SAN FRANCISCO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced that Chief Executive Officer, Natalie Holles, will participate in a...
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Third Harmonic Bio, Inc. (NASDAQ: THRD)
NEW YORK , Feb. 22, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Third Harmonic Bio, Inc. (NASDAQ: THRD) on behalf of the company's shareholders. The investigation seeks to determine whether Third Harmonic Bio's directors breached their...
Third Harmonic Bio Appoints Christopher Murphy as Chief Financial and Business Officer and Provides Business Update
Chris brings extensive enterprise-level leadership experience in business development, commercial operations, and corporate strategy
Are You Looking for a Top Momentum Pick? Why Third Harmonic Bio, Inc. (THRD) is a Great Choice
Does Third Harmonic Bio, Inc. (THRD) have what it takes to be a top stock pick for momentum investors? Let's find out.
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Third Harmonic Bio, Inc. (NASDAQ: THRD)
NEW YORK , Nov. 9, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Third Harmonic Bio, Inc. (NASDAQ: THRD) on behalf of the company's shareholders. The investigation seeks to determine whether Third Harmonic Bio's directors breached their...
Third Harmonic Bio Announces Third Quarter 2023 Financial Results
On track to file a U.S. Investigational New Drug (IND) application for THB335 and initiate clinical studies in 1H'24
Third Harmonic Bio Announces Leadership Changes
SAN FRANCISCO, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the transition of Adrian S. Ray, Ph.D., from Chief Scientific...
Third Harmonic Bio to Participate in the Morgan Stanley Global Healthcare Conference
SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced that Chief Executive Officer Natalie Holles will participate in a...
Third Harmonic Bio Announces Second Quarter 2023 Financial Results
Introduced next-generation oral KIT inhibitor product candidate THB335, which retains the potency and selectivity of first-generation oral KIT inhibitor, THB001, with differentiated metabolic, distribution, and physicochemical profile
Source: https://incomestatements.info
Category: Stock Reports